Format

Send to

Choose Destination
Muscle Nerve. 2016 Oct;54(4):783-5. doi: 10.1002/mus.25145. Epub 2016 Jul 7.

A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy.

Author information

1
Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA. diana.abbott@utah.edu.
2
Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
3
Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
4
George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah.

Abstract

INTRODUCTION:

The risk of cancer in patients diagnosed with myotonic dystrophy (DM) is reported for the homogeneous Utah population.

METHODS:

Clinical data accessed from the largest Utah healthcare providers have been record-linked to the Utah Population Database, a population-based resource also linked to the Utah Cancer Registry. Relative risks were estimated for 36 cancers of different types in 281 DM patients.

RESULTS:

Testicular cancer (relative risk [RR] = 10.74; 95% confidence interval [CI], 1.91-38.79), endometrial cancer (RR = 6.98; 95% CI, 1.24-25.22), and non-Hodgkin lymphoma (RR = 4.25; 95% CI, 1.16-12.43) were all observed at significant excess in DM patients.

CONCLUSIONS:

This study confirms an overall increased risk of cancer in DM. Individuals diagnosed with DM might benefit from risk counseling. Muscle Nerve 54: 783-785, 2016.

KEYWORDS:

UPDB; cancer; myotonic dystrophy; neuromuscular disease; relative risk

PMID:
27064430
PMCID:
PMC5824717
DOI:
10.1002/mus.25145
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center